These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 8730122

  • 21. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
    Mayes MD, O'Donnell D, Rothfield NF, Csuka ME.
    Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
    [Abstract] [Full Text] [Related]

  • 22. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C, Harding S, Khimdas S, Bonner A, Canadian Scleroderma Research group, Baron M, Pope J.
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [Abstract] [Full Text] [Related]

  • 23. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
    Rook AH, Freundlich B, Jegasothy BV, Perez MI, Barr WG, Jimenez SA, Rietschel RL, Wintroub B, Kahaleh MB, Varga J.
    Arch Dermatol; 1992 Mar; 128(3):337-46. PubMed ID: 1550365
    [Abstract] [Full Text] [Related]

  • 24. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B, Zalewska A, Sysa-Jedrzejowska A.
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [Abstract] [Full Text] [Related]

  • 25. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K.
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [Abstract] [Full Text] [Related]

  • 26. Churg-Strauss syndrome: serum markers of lymphocyte activation and endothelial damage.
    Schmitt WH, Csernok E, Kobayashi S, Klinkenborg A, Reinhold-Keller E, Gross WL.
    Arthritis Rheum; 1998 Mar; 41(3):445-52. PubMed ID: 9506572
    [Abstract] [Full Text] [Related]

  • 27. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
    Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW.
    Clin Exp Rheumatol; 2001 Mar; 19(1):69-74. PubMed ID: 11247328
    [Abstract] [Full Text] [Related]

  • 28. Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis.
    Tsao TC, Huang CC, Chiou WK, Yang PY, Hsieh MJ, Tsao KC.
    Int J Tuberc Lung Dis; 2002 Aug; 6(8):720-7. PubMed ID: 12150485
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A multicenter study to evaluate a novel assay for quantitation of soluble interleukin 2 receptor in renal transplant recipients.
    Schroeder TJ, Helling T, McKenna RM, Rush D, Jeffrey JR, Brewer B, Martin LA, Traylor D, Fisher RA, First MR.
    Transplantation; 1992 Jan; 53(1):34-40. PubMed ID: 1733082
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Gamma-interferon and soluble interleukin 2 receptor in tuberculous pleural effusion.
    Kim YK, Lee SY, Kwon SS, Kim KH, Moon HS, Song JS, Park SH.
    Lung; 2001 Jan; 179(3):175-84. PubMed ID: 11891607
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.
    Salvarani C, Macchioni P, Boiardi L, Rossi F, Casadei Maldini M, Mancini R, Beltrandi E, Spacca C, Lodi L, Portioli I.
    J Rheumatol; 1992 Jul; 19(7):1100-6. PubMed ID: 1512765
    [Abstract] [Full Text] [Related]

  • 36. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
    Hara T, Ogawa F, Muroi E, Komura K, Takenaka M, Hasegawa M, Fujimoto M, Sato S.
    J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors.
    Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N.
    Arthritis Rheum; 2004 Jan; 50(1):216-26. PubMed ID: 14730619
    [Abstract] [Full Text] [Related]

  • 38. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S, Remitz A, Varga J, Ceska M, Effenberger F, Jimenez S, Uitto J.
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [Abstract] [Full Text] [Related]

  • 39. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
    Dziankowska-Bartkowiak B, Zebrowska A, Wagrowska-Danielewicz M, Kobos J, Waszczykowska E.
    Przegl Lek; 2009 Feb; 66(12):1040-5. PubMed ID: 20514902
    [Abstract] [Full Text] [Related]

  • 40. Serum soluble CD4 and CD8 levels in polymyalgia rheumatica.
    Salvarani C, Boiardi L, Macchioni P, Casadei Maldini M, Mancini R, Beltrandi E, Rossi F, Portioli I.
    J Rheumatol; 1994 Oct; 21(10):1865-9. PubMed ID: 7837152
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.